Biocon Issuer Summary

Report date: 2026-05-13
Issuer: Biocon Limited
Relevant debt layers: Biocon Limited bank facilities; Biocon Biologics Limited credit profile; Biocon Biologics Global Plc USD 800 million senior secured notes due 2029
Primary equity listing: BSE / NSE India

1. Business Snapshot and Recent Developments

Biocon Limited (Biocon) is a global biopharmaceutical group based in India. It should not be viewed simply as a domestic Indian pharmaceutical company. Rather, it should be analysed as an issuer that combines biosimilars, generic pharmaceuticals, complex small-molecule APIs, and contract research, development and manufacturing, and sells products in international markets including the US, Europe, Canada, Japan, Australia and emerging markets. As of May 2026, the central credit questions are how far the integration of its biosimilars subsidiary Biocon Biologics Limited (BBL), the absorption of the commercialised biosimilars business acquired from Viatris, the USD secured notes issued by the BBL group in 2024, and the capital strengthening and deleveraging undertaken from 2025 into 2026 translate into consolidated credit strength and recovery resources for bondholders.

In Biocon’s consolidated disclosures, the business is broadly divided into Biosimilars, Generics, and CRDMO / Syngene. Biosimilars is centred on BBL and covers biosimilars in areas including insulin, oncology, immunology, ophthalmology and bone-related diseases. Generics includes APIs, complex generic formulations and GLP-1 peptides at Biocon and its subsidiaries. CRDMO is centred on the listed subsidiary Syngene International Limited (Syngene), which undertakes discovery research, development and contract manufacturing. What matters for credit investors is that, while these three businesses appear integrated in consolidated earnings, debt, collateral, ratings, minority interests and access to cash are not the same across the group.

FY26 was a year in which Biocon advanced both “post-integration margin improvement” and “capital structure simplification.” According to the FY26 full-year results released on 7 May 2026, revenue from operations, which corresponds to consolidated revenue, was Rs 16,927 crore, total income was Rs 17,270 crore, EBITDA was Rs 3,798 crore, and the EBITDA margin was 22%. The company explained that, after adjusting for one-off generic lenalidomide sales and the BFI divestment gain in FY25, FY26 operating revenue increased 13% year on year, EBITDA increased 25%, and the EBITDA margin improved by about 200bp. This is evidence of the expansion of the biosimilars commercial platform and progress in integration work.

However, it is premature to read the FY26 improvement as stable credit improvement in itself. FY26 reported net profit was only Rs 386 crore, and net profit before exceptional items was Rs 436 crore, meaning that profit attributable to shareholders remains thin compared with the scale of consolidated EBITDA. FY26 included exceptional items related to integration, while depreciation and amortisation was Rs 1,957 crore and finance charges were Rs 990 crore. The biosimilars business acquired from Viatris materially increased revenue and the business platform, but it also increased goodwill, intangible assets, borrowings, R&D, capital expenditure and regulatory obligations at the same time. Credit analysis should therefore prioritise whether EBITDA is converting into cash and into debt reduction and refinancing capacity, rather than focusing only on revenue growth.

On recent management developments, Shreehas Tambe became CEO & Managing Director of Biocon Limited effective 1 April 2026, while Kedar Upadhye became CFO. In the FY26 results, the company said it had created an integrated biopharma entity combining biosimilars and generics, and positioned FY27 as a transition from “Preserve” to “Consolidate.” For bond investors, this language indicates progress on integration synergies and commercialisation, but it also means that integration remains a credit-monitoring item. If the integration succeeds, commercial operations, manufacturing, R&D and the capital structure should become simpler. If it fails, costs, inventory, regulatory responses and launch delays could slow the pace of debt reduction.

Recent capital-structure events have also changed the profile of Biocon. In 2022, BBL’s acquisition of Viatris’s biosimilars business significantly expanded the Biocon group’s business scale and international commercial platform, but it also caused group leverage to rise sharply. In October 2024, Biocon Biologics Global Plc issued USD 800 million of senior secured notes due 2029 and advanced the refinancing of BBL’s existing debt. From 2025 into 2026, Biocon Limited raised capital through a QIP and proceeded with transactions to address structured debt, Viatris-related CCPS, and the move toward making BBL a wholly owned subsidiary. S&P Global Ratings upgraded BBL’s long-term issuer rating to BB+ in January 2026, while Fitch affirmed BBL’s BB- rating in February 2026 and revised the issuer rating outlook to Positive. Both rating actions reflect deleveraging expectations, but the differences in rating levels and the debt instruments being rated should not be conflated.

When this report refers to “BBL integration,” three meanings should be distinguished. The first is the commercial and operational integration of the biosimilars business acquired from Viatris, including sales networks, manufacturing, R&D and organisational operations. The second is the transaction by which Biocon Limited addresses BBL minority interests and Viatris-related CCPS, thereby simplifying its ownership and capital structure. The third is any change to the bond documentation for the BBGP notes, including guarantors, collateral, the restricted group and covenants; this remains unverified in this report. Even if business integration and full ownership advance, this is not treated as automatically strengthening the legal protections of the BBGP notes.

As a business, Biocon is supported by expanded access to medicines and growth in biosimilars. As a credit, however, it is an issuer for which investors must continuously monitor biosimilar price competition, dependence on the US market, regulatory and quality risks including the FDA, significant intangible assets and R&D investment, subsidiary debt structure, and minority interests in Syngene. The current Biocon is neither a simple high-growth pharmaceutical company nor a stable domestic pharmaceutical company. Business quality appears to be improving, but the credit assessment depends on whether deleveraging proceeds as planned and whether biosimilars margins can absorb regulatory, pricing and quality risks.

2. Industry Position and Franchise Strength

Biocon’s business platform consists of a combination of commercialised biosimilars, complex generics, CRDMO capabilities and a global manufacturing network. According to the company’s factsheet and FY26 release, Biocon operates in more than 120 countries and has 12 commercialised biosimilars, more than 30 generic formulations and more than 20 biosimilar development assets. This shows that it is not a biotech company concentrated on single-product risk at the R&D stage, but a pharmaceutical operating company with commercialised products and manufacturing and sales infrastructure. That said, biosimilars involve more demanding development, manufacturing and regulatory processes than ordinary small-molecule generics. They have entry barriers, but approval delays and manufacturing quality issues can also have a large impact on credit strength.

Biosimilars is the core of Biocon’s franchise. BBL has incorporated the commercial platform acquired from Viatris and expanded sales across the US, Europe, Canada, Australia, Japan and emerging markets. In the FY26 results announced on 7 May 2026, Biosimilars FY26 revenue from operations was Rs 10,431 crore, up 16% year on year, while EBITDA was Rs 2,751 crore and the EBITDA margin was 26%. The important point is that Biosimilars is not merely a growth business; it has become the centre of consolidated EBITDA. At the same time, biosimilars are affected by originator defence, multiple entrants, reimbursement, tenders, litigation and timing of market entry, so the strength of the product base should not be equated directly with pricing power.

Generics does not have the same EBITDA scale as Biosimilars, but it is an important complementary business supporting Biocon’s manufacturing and development capabilities. FY26 Generics revenue from operations was Rs 3,168 crore, up 17% year on year excluding one-off generic lenalidomide sales in FY25. Progress related to generic Liraglutide was also confirmed in Q4 FY26, but US generic pricing, FDA inspections, API supply, facility ramp-up and price erosion from competition are constraints.

CRDMO / Syngene supports Biocon’s revenue diversification, but it should not be overestimated as a repayment source for parent-company debt. Syngene, one of India’s major CRDMO companies, recorded FY26 revenue from operations of Rs 3,739 crore and an EBITDA margin of 25%. At the same time, FY26 showed the impact of a single large biologics client, meaning it is exposed to customer concentration and facility utilisation. Because Syngene is a listed subsidiary and Biocon’s ownership ratio in the FY25 annual report was 52.5%, its earnings are consolidated, but cash cannot be freely moved to service parent-company or BBL debt.

Another central element in assessing Biocon’s franchise is manufacturing quality. For biosimilars and complex generics, not only product approvals but also inspections and GMP status from the FDA, EMA, PMDA, Health Canada and other regulators determine business continuity. The FY25 annual report and company statements indicate that Biocon Biologics-related facilities in Bengaluru and Johor Bahru underwent US FDA inspections and received VAI (Voluntary Action Indicated) status. VAI is not normally a classification that immediately implies major enforcement action, but for bond investors it is not equivalent to “no issue”; it is a signal that remedial actions should continue to be monitored. The larger the number of approved products, the more easily even small manufacturing quality delays can affect revenue, inventory, tenders and launch timing.

Dependence on the US market is also a standalone issue. CRISIL notes that about 46% of FY25 consolidated revenue was directed to the US market, and that changes in US regulation or the pricing and competitive environment could significantly affect Biocon’s business and finances. The US market is large in terms of volume, pricing, approvals and reimbursement, and success there can improve margins. Conversely, drug-pricing policy, FDA warning/inspection issues, entry of competing products, litigation or less favourable contracting would affect not only revenue but also inventory, R&D, recovery of capital expenditure and debt reduction. Biocon’s international business platform supports credit strength, but US dependence also increases downside sensitivity.

3. Segment Assessment

In assessing Biocon’s segments, it is natural to focus on Biosimilars while positioning Generics and CRDMO as complementary. Biosimilars is the centre of revenue scale and EBITDA, Generics offers growth potential in complex small molecules and GLP-1 products, and CRDMO is a contract business with relatively different demand drivers. However, earnings quality differs by segment, and so does cash access. Syngene in particular is consolidated but is a listed subsidiary with a significant minority shareholder base, so from the standpoint of bondholders, “included in consolidated EBITDA” must be distinguished from “freely available repayment resources.”

Biosimilars is the business that determines both the upside and downside of credit strength. FY26 included several approval and launch developments, including the US launches of Bosaya and Aukelso, Health Canada approvals related to Denosumab, and progress related to generic Liraglutide and insulin. These are growth drivers, but they are also execution risks. Even after approval, biosimilars do not immediately guarantee high margins; they are affected by supply capacity, adoption by physicians, patients and payors, pricing, contracts, litigation settlements and the number of competing products. The FY26 Biosimilars EBITDA margin of 26% is strong, but maintaining this level requires the balance among volume growth, product mix, manufacturing yield and R&D burden not to deteriorate.

Generics can be misread because of the comparison with one-off lenalidomide sales in FY25. The company’s FY26 disclosure states that Generics revenue increased 17% excluding the one-off impact of lenalidomide. This indicates underlying growth, but it also means that one-off sales look large in historical comparisons. The Generics EBITDA margin in Q4 FY26 was 8%, lower than Biosimilars and Syngene. Accordingly, Generics is a source of growth and product expansion, but at this stage it is more appropriate to view it as a complementary business that modestly reduces concentration in Biosimilars, rather than as the main support for consolidated credit strength.

GLP-1-related opportunities in Generics tend to attract attention, but new product approvals should not be brought forward into the credit case as revenue improvement until monetisation, gross margin, inventory, manufacturing capacity and regulatory response are observed. The same applies to Syngene: it contributes to consolidated EBITDA, but as a listed subsidiary it has minority interests, a board, business investment needs and a dividend policy. It should therefore not be assumed that Syngene’s cash can be freely applied to debt service at Biocon Limited or BBL.

Across segments, Biocon has a structure in which Biosimilars drives growth and margins, Generics provides product and technology complementarity, and Syngene provides revenue diversification. The main risks are regulation, manufacturing and pricing in Biosimilars; competition and approvals in Generics; and customer concentration and capex in Syngene. Credit investors need to track not only consolidated revenue and EBITDA, but also which segment generates cash, in which legal entity that cash is generated, and which debt it can reach.

4. Financial Profile and Analysis

Biocon’s financial profile improved in FY26, but from a credit standpoint it remains in the phase of confirming improvement. FY26 operating revenue was Rs 16,927 crore, total income was Rs 17,270 crore, and EBITDA was Rs 3,798 crore. FY25 reported EBITDA appears larger than FY26 at Rs 4,374 crore, but FY25 included one-off items such as the BFI divestment gain. The company’s FY25 adjusted EBITDA was Rs 3,036 crore, and on comparison with this adjusted figure, FY26 EBITDA increased 25%. Credit analysis should therefore focus on underlying improvement after adjusting for one-off items, rather than reported headline figures.

FY26 profitability was supported by margin improvement in Biosimilars. Biosimilars recorded FY26 revenue of Rs 10,431 crore, EBITDA of Rs 2,751 crore and an EBITDA margin of 26%, making it the main support for consolidated EBITDA. However, against consolidated EBITDA of Rs 3,798 crore, finance charges were Rs 990 crore and depreciation and amortisation was Rs 1,957 crore, so the drop from EBITDA to pre-tax profit and final profit is substantial. This indicates that Biocon’s operating cash flow is improving enough to support debt and investment, but it is difficult to say that the cushion is large.

The FY26 balance sheet clearly improved from FY25. As of 31 March 2026, non-current borrowings were Rs 10,746 crore and current borrowings were Rs 4,078 crore, resulting in total gross borrowings of Rs 14,824 crore. Gross borrowings were Rs 17,755 crore as of 31 March 2025, so they decreased by about Rs 2,931 crore. Cash and cash equivalents were Rs 2,417 crore, other bank balances were Rs 777 crore, and current investments were Rs 690 crore. This report treats gross borrowings less cash and cash equivalents and other bank balances as provisional consolidated net debt. On this calculation, net debt at FY26-end was about Rs 11,630 crore, or about Rs 10,940 crore on a reference calculation that also includes current investments as liquidity. Compared mechanically with FY26 EBITDA of Rs 3,798 crore, provisional consolidated net debt / EBITDA appears to be about 2.9x to 3.1x.

This improvement is credit positive, but three caveats apply. First, the net debt above is a provisional measure on a Biocon Limited consolidated basis including Syngene, and does not indicate cash freely available at Biocon Limited parent or BBL on a standalone basis. Second, cash and cash equivalents at FY26-end decreased from FY25-end, and liquidity quality cannot be assessed from cash balances alone without looking at undrawn bank lines, maturity distribution, secured notes and the location of subsidiary cash. Third, FY26 gross borrowings include BBL’s USD notes and bank debt, but the maturities, collateral, currencies and covenants of individual debt instruments could not be verified in detail in this report. A simple consolidated net debt / EBITDA ratio is not sufficient to measure risk for bondholders.

As of December 2025, CRISIL estimated Biocon’s FY25 net debt / EBITDA at 4.1x and the September 2025 figure at 3.0x, and expected the ratio to improve in the short term to between 2.5x and below 3.0x. The provisional consolidated net debt / EBITDA calculated from the FY26-end company factsheet is also broadly close to this range. At the same time, CRISIL identifies sustained operating margins below 20-22%, net debt / EBITDA remaining above 3.5-3.6x, capex or M&A funded by additional debt, and working-capital deterioration as rating downside factors. In other words, the current credit profile assumes continuing deleveraging.

As the FY26 audited cash flow statement had not been obtained as of the preparation of this report, this report does not make definitive statements about operating cash flow or FCF. This is an important limitation. For an issuer such as Biocon, where R&D, capex, working capital, regulatory approvals, inventory and integration costs are significant, higher EBITDA does not necessarily mean sufficient residual FCF. Whether the FY26 EBITDA improvement actually translated into operating cash flow, post-capex FCF and debt repayment needs to be rechecked in the FY26 annual report and cash flow statement. At this stage, deleveraging is confirmed from lower gross borrowings and higher equity on the balance sheet, but it should not be concluded that the improvement came solely from FCF.

The central financial interpretation is that Biocon improved its capital structure and margins in FY26, but remains an issuer with meaningful debt, interest expense, amortisation, R&D, capex and minority-interest burdens. If Biosimilars margins are maintained, Generics and Syngene do not deteriorate significantly, and capital-structure simplification continues, credit strength should be able to remain on an improving trend. Conversely, if US pricing pressure, FDA inspections, product launch delays and working-capital deterioration coincide, EBITDA improvement may not easily remain available for debt reduction. Financials are improving, but the cushion is not yet large enough to confirm broad stress resilience.

5. Structural Considerations for Bondholders

For Biocon bondholders, the most important issue is which legal entity has debt, which legal entity has cash flow, and which creditors can access which assets, guarantees and collateral. Biocon Limited’s consolidated figures include BBL, Syngene and other subsidiaries. However, Biocon Limited’s domestic bank facilities, BBL’s credit profile, the USD 800 million senior secured notes of Biocon Biologics Global Plc, and cash at Syngene as a listed subsidiary are not in the same legal position.

The USD notes of Biocon Biologics Global Plc are the central credit seen in international bond markets within the Biocon group. According to the company announcement in October 2024, BBL issued USD 800 million of 6.67% senior secured notes due 2029 and listed them on the SGX-ST. The issuer is Biocon Biologics Global Plc, described as a wholly owned subsidiary of BBL. The purpose of issuance was to refinance existing long-term debt of about USD 1.1 billion, together with a new syndicated facility. This transaction improved liquidity and the maturity profile, but because the notes are secured, the collateral, guarantors, restrictive covenants, restricted payments, change of control provisions and early redemption provisions should be checked individually. Secured status can support recovery prospects, but because the collateral scope, guarantors and collateral value have not been verified, this report does not quantitatively assess recovery superiority at this stage.

At present, it cannot be stated that holders of the USD notes have an unconditional guarantee from Biocon Limited itself. S&P and Fitch releases indicate that BBL’s ratings are affected by its relationship with parent Biocon Limited and by deleveraging progress, but parent support expectations in credit terms are different from legal guarantees. Biocon Limited’s move to make BBL a wholly owned subsidiary increases the group’s strategic integration, but it does not mean that the debtor, guarantors, collateral or covenants of the existing USD notes automatically move to Biocon Limited itself. Before investing in the bonds, the offering circular, indenture and SGX disclosures need to be reviewed.

BBL ownership and capital-structure simplification can be credit positive. Biocon’s December 2025 release announced a strategic transaction to make BBL a wholly owned subsidiary of Biocon Limited, with the intention of simplifying the structure and strengthening the consolidated balance sheet. S&P’s January 2026 release explains that the USD 1 billion of CCPS held by Viatris was addressed through equity share swaps and cash consideration, and that about USD 460 million of new equity was used for the cash payout. This reduces complexity from minority interests and structured liabilities. However, actual legal completion, remaining consideration, and the impact on the terms of each debt instrument need to be rechecked in the FY26 annual report and stock exchange filings.

The treatment of Syngene is also important. Consolidated financial analysis includes Syngene’s revenue, EBITDA and cash. However, Syngene is a listed company, and Biocon’s ownership ratio was 52.5% as of FY25. Although the parent holds a majority stake, Syngene’s capital policy, business investment and dividends are constrained by minority shareholders and listed-company governance. It should not be assumed that the debtor at Biocon Limited or BBL has direct access to Syngene’s cash or assets. Even if consolidated leverage appears to improve, investors need to verify any mismatch between the location of debt and the location of cash.

The structural conclusion is that Biocon is improving on a consolidated basis, but bondholders cannot rely on consolidated metrics alone. Domestic bank creditors of Biocon Limited, holders of BBGP secured notes, and Syngene shareholders and creditors sit at different legal layers. Recovery resources, collateral, guarantees, dividends and access to subsidiary cash are determined by contracts, so verification of the BBGP notes documentation is essential in any individual bond investment.

6. Capital Structure, Liquidity and Funding

Biocon’s capital structure clearly improved in FY26. Gross borrowings at FY26-end were Rs 14,824 crore, down from Rs 17,755 crore at FY25-end. Total equity increased to Rs 36,622 crore, and equity attributable to owners also increased to Rs 34,032 crore. This reflects the impact of the QIP, BBL-related ownership treatment, the decline in minority interests and structured debt repayment. The credit positive element in the capital structure is that debt decreased and equity depth increased.

However, from a liquidity standpoint, it is difficult to simply say that “cash is abundant.” As of 31 March 2026, cash and cash equivalents were Rs 2,417 crore, other bank balances were Rs 777 crore, and current investments were Rs 690 crore. By comparison, current borrowings were Rs 4,078 crore. Cash and bank balances alone do not fully cover current borrowings, though the level becomes closer if current investments are included. In addition, Biocon has bank facilities, access to domestic capital markets, BBL notes and Syngene’s financial flexibility. However, these are consolidated figures including Syngene and do not directly show freely available cash at the parent company or BBL on a standalone basis. Undrawn committed lines, maturity distribution, debt by currency, and the secured/unsecured split are unverified in this report.

In its December 2025 rating rationale, CRISIL assessed Biocon’s liquidity as Strong, citing expected FY26 cash accruals of Rs 2,500-3,000 crore and unencumbered liquid surplus of about Rs 6,500 crore as of September 2025. This supports the short-term liquidity assessment. However, the subsequent QIP, CCPS treatment, structured debt repayment and change in FY26-end cash balances need to be taken into account, and whether liquidity is robust cannot be concluded without confirming undrawn lines and the maturity schedule.

BBL’s USD notes are both evidence of capital-market access and a future refinancing issue. The maturity is in 2029, so it is not an immediate wall, but BBL’s rating, Biocon’s consolidated leverage, US biosimilars earnings, FDA status, interest rates and the high-yield market environment will determine refinancing conditions. Over the medium term, the key issue is whether debt reduction can continue through operating cash flow and FCF, rather than through equity raising.

Liquidity monitoring should focus on three points. First is coverage of current borrowings and near-term maturities by cash and undrawn lines. Second is the maturity, collateral, covenants and restricted payment capacity of the BBL secured notes and bank debt. Third is the location of subsidiary cash, including Syngene, and the ability to move it to the parent company. Consolidated cash is not liquidity for bondholders if the debtor cannot use it when needed.

7. Rating Agency View

When looking at Biocon’s ratings, domestic-scale and international-scale ratings, parent and subsidiary, and bank facilities and secured notes need to be separated. On 16 December 2025, CRISIL reaffirmed CRISIL AA+/Stable and CRISIL A1+ on Biocon Limited’s Rs 250 crore bank facilities. This is an Indian domestic-scale rating and is a credit assessment of Biocon Limited’s domestic bank facilities. It should not be mechanically compared with ratings on BBL’s US dollar foreign-currency bonds or with default probability from the standpoint of international investors.

CRISIL views Biocon group’s established biopharmaceutical business platform, diversified revenue sources, development pipeline and operational capabilities as strengths, while positioning financial risk as average but improving. CRISIL estimated FY25 net debt / EBITDA at 4.1x and the September 2025 figure at 3.0x, and expected the ratio to improve in the near future to between 2.5x and below 3.0x through the QIP, debt reduction and structured debt retirement. It also identifies sustained operating margins below 20-22%, net debt / EBITDA remaining above 3.5-3.6x, capex/M&A funded by additional debt, and working-capital deterioration as downside factors. This shows that, despite the high domestic rating, Biocon’s credit strength assumes deleveraging and sustained margins.

For BBL, the views of international rating agencies are more directly relevant to USD notes investors. On 28 January 2026, according to the company release, S&P Global Ratings raised BBL’s long-term issuer rating from BB to BB+ and assigned a Stable outlook to the issuer rating. It also upgraded the senior secured notes rating of Biocon Biologics Global Plc to BB+. According to S&P’s company release, the upgrade reflected Biocon’s capital-structure simplification, reduction in structured debt, treatment of the USD 1 billion CCPS held by Viatris, revenue growth from new products and industry trends, and its assessment of financial policy. S&P also explained that debt-to-EBITDA rose from about 2x in FY22 to about 7x in FY24 after the Viatris biosimilars acquisition, showing that the current improvement is a recovery process from high post-acquisition leverage.

On 7 February 2026, according to the company release, Fitch affirmed BBL’s Long-Term Foreign-Currency IDR at BB- and revised the issuer rating outlook from Stable to Positive. Fitch cited expectations that financial leverage would decline sustainably after Biocon Limited used the proceeds of its recent equity issuance to reduce debt. Fitch affirmed the BB rating on Biocon Biologics Global Plc’s USD 800 million secured notes. The difference between S&P’s BB+ and Fitch’s BB-/BB may reflect differences in each rating agency’s views on parent-subsidiary linkage, collateral assessment, and business and financial risk. This report does not simplify the difference into “which is correct,” but treats it as a difference in rating target, timing and methodology.

The cautions in using the ratings for investment decisions are clear. CRISIL AA+ is an Indian domestic-scale rating on Biocon Limited’s domestic bank facilities and does not indicate the legal protection of the BBGP notes. S&P and Fitch’s BBL ratings are relevant to BBL and the BBGP notes, but they are not international foreign-currency bond ratings of Biocon Limited itself. Ratings are an important external check, but bondholders need to review terms and structure separately.

8. Credit Positioning

Biocon’s credit positioning has a dual character: an Indian domestic high-rated biopharmaceutical group and an international high-yield biosimilars subsidiary credit. From a domestic perspective, as indicated by CRISIL AA+, Biocon has an established business platform, revenue diversification, capital-market access and a deleveraging plan. From the perspective of international US dollar bonds, BBL/BBGP notes are BB-area high-yield bonds, and investors need to review post-Viatris-acquisition high leverage, biosimilars execution risk, the subsidiary structure, and collateral and guarantee terms. Not confusing these two perspectives is the starting point for analysing Biocon credit.

From a business-risk perspective, Biocon operates in an area with higher barriers to entry than ordinary small-molecule generics. Biosimilars require more demanding development, manufacturing, regulation and commercialisation. If successful, they can lead to high profitability and an international platform. The FY26 Biosimilars EBITDA margin of 26% shows this potential. At the same time, biosimilars are highly competitive and are strongly affected by product-by-product launch timing, healthcare systems, pricing and supply stability. Biocon is therefore higher quality than a simple commodity generics company, but more volatile than a simple stable healthcare services issuer.

From a financial-risk perspective, Biocon is an issuer repairing itself from excessive post-acquisition leverage. As S&P’s release shows, debt-to-EBITDA rose significantly in FY24 after the Viatris acquisition and has since been brought back down through the QIP, structured debt repayment, simplification of BBL ownership and capital structure, and earnings improvement. FY26-end simple net debt / EBITDA is around 3x, which is not excessively weak for a high-yield credit, but this is a provisional consolidated metric including Syngene and is not adjusted for free cash or the location of debt. Given R&D/Capex, interest expense, intangible asset amortisation and regulatory risk, the cushion cannot be called large. Whether leverage declines further or rises again due to M&A or capex will be the medium-term dividing line.

From a structural-risk perspective, investors in the BBL notes should view Biocon’s consolidated improvement positively, but should also confirm the scope of the legal debtor. BBL is strategically important to Biocon, and its relationship with the parent is reflected in S&P and Fitch’s views. However, expectations of strategic parent support are different from an explicit guarantee or pari passu creditor protection. The secured status of the BBGP notes may support recovery prospects, but actual protection cannot be assessed without confirming the details of collateral scope, guarantors, restricted subsidiaries, dividend limitations and financial restrictions. At this stage, this report does not quantify recovery advantage from secured status.

On market relative value, this report does not have access to Bloomberg or other price and spread data and therefore does not make conclusions on cheapness or richness. If comparing Biocon/BBL, relevant reference points would include Indian high-yield foreign-currency bonds, Asian healthcare and pharmaceutical issuers, BB/Ba-range post-acquisition deleveraging credits, and expected recovery from secured notes collateral. Qualitatively, Biocon has growth and deleveraging improvement, but US regulatory, pricing, quality and subsidiary-structure risks remain, so it is not a simple stable BB credit. A strong investment judgment should not be made before market levels are confirmed.

9. Key Credit Strengths and Constraints

The first factor supporting Biocon’s credit strength is its business platform in biosimilars. BBL has commercialised products and an international sales platform, and in FY26 Biosimilars led consolidated growth and EBITDA. Biosimilars have structural demand from healthcare cost reduction and expanded access, rather than merely a short-term product cycle. Biocon’s product deployment in the US, Europe and emerging markets, and its pipeline of multiple products, reduce single-product risk.

The second support is capital-structure improvement. FY26-end gross borrowings declined from FY25-end, and total equity increased. S&P and Fitch’s 2026 rating actions recognise Biocon’s debt reduction and capital-structure simplification. CRISIL also expected net debt / EBITDA to improve through the QIP and structured debt repayment. Recovery from high leverage after the Viatris acquisition is the most important positive factor in assessing current credit strength. However, because FY26 operating cash flow and FCF have not yet been confirmed, this assessment is a provisional judgment based on EBITDA, debt balances and equity.

The third support is revenue diversification. Although Biosimilars is central, Generics and Syngene complement consolidated revenue. Generics broadens the product platform through GLP-1, complex generics and APIs, while Syngene has different demand drivers as a CRDMO.

The main constraint, first, is US dependence and regulatory and pricing risk. If, as CRISIL notes, about 46% of FY25 consolidated revenue was directed to the US, changes in US drug pricing, reimbursement, the FDA, competition, litigation and supply contracts have a large effect on consolidated credit strength. Success in the US can raise margins, but a stumble in the US would weaken the entire Biosimilars growth story.

The second constraint is manufacturing quality risk. In biosimilars, the regulatory status of manufacturing facilities is directly tied to revenue. VAI does not immediately mean a sales suspension, but delays in remediation or new inspection issues can affect approvals, launches, supply, tender participation and inventory. Biocon’s credit strength depends not only on R&D, but also on continuing GMP compliance.

The third constraint is the weight of debt and fixed charges. Deleveraging advanced in FY26, but gross borrowings remain Rs 14,824 crore and finance charges are Rs 990 crore. Depreciation and amortisation is also large at Rs 1,957 crore, with intangible assets, facilities and post-acquisition accounting burdens pressuring profit. Even if EBITDA is strong, credit improvement will not be as strong as it appears if final profit and FCF remain thin.

The fourth constraint is group structure and cash access. BBGP notes, BBL, Biocon Limited and Syngene sit at different legal layers, and the locations of cash, debt and collateral differ. Syngene is a listed subsidiary with significant minority interests and may not be freely usable as a repayment source for parent-company debt. BBL becoming a wholly owned subsidiary simplifies the structure, but this must be verified separately from the legal protection and collateral scope of the secured notes.

The fifth constraint is the continuing burden of R&D and capex. Biosimilars, GLP-1, complex generics and manufacturing capacity expansion are sources of future earnings but also involve upfront investment and uncertainty. CRISIL estimates organic capex at about $200-250 million per year, and R&D is also large as a share of revenue. Commercialisation as planned would be positive, but approval delays, price declines, litigation or quality issues would delay investment recovery.

Taken together, Biocon’s credit strength is improving but conditional. The business platform, biosimilars growth and capital-structure improvement are supports, but US regulation and pricing, manufacturing quality, debt structure, FCF and access to subsidiary cash determine the ceiling.

10. Downside Scenarios and Monitoring Triggers

The most important downside scenario for Biocon is a simultaneous slowdown in Biosimilars growth and decline in margins. If prices fall in the US or Europe, tender terms worsen, originator manufacturers defend aggressively, competing biosimilars increase, or new product launches are delayed, the Biosimilars EBITDA margin of 26% confirmed in FY26 may not be maintained. Because Biosimilars is the core of consolidated EBITDA, weakness in this segment would directly affect net debt / EBITDA and refinancing capacity.

The second downside scenario is a manufacturing quality issue raised by the FDA or another major regulator. Biocon Biologics’ Bengaluru and Malaysia facilities are related to US-bound products and new product approvals. VAI status itself is not a major enforcement action, but if additional inspections result in OAI, warning letters, approval delays or supply constraints, the impact on revenue and reputation would be significant. Specific items to monitor include FDA inspection classification, EIRs, company statements, facility-specific approvals, launch timing, and tender or customer announcements related to product supply.

The third downside scenario is a halt in deleveraging. FY26-end net debt / EBITDA improved to around 3x on a simple calculation, but FCF could remain thin due to R&D, capex, working capital, integration costs, tax, dividends and constraints on subsidiary cash. If net debt / EBITDA returns to above 3.5x and operating margins remain below 20-22%, Biocon would approach CRISIL’s downside sensitivities. Metrics to monitor include gross borrowings, current borrowings, cash and bank balances, net debt / EBITDA, EBITDA / finance charges, operating cash flow, FCF and capex.

The fourth downside scenario is crystallisation of structural risk in the BBL secured notes. If BBL encounters operational difficulties and Biocon Limited needs to support it, parent-company capital allocation, BBL’s restricted payments, collateral, guarantees and covenants would become issues. Conversely, if Biocon Limited’s credit weakens, support expectations for BBL and its ratings could also be affected. BBGP notes holders should confirm not only Biocon consolidated deleveraging, but also BBL standalone cash, debt, collateral, guarantors, maturities and covenant headroom.

The fifth downside scenario is a slowdown in Syngene growth or a customer concentration issue. Syngene supports consolidated diversification, but FY26 showed the impact of a single large biologics client. If CRDMO demand slows, facility utilisation declines and capex recovery is delayed, the segment’s ability to complement consolidated profit would weaken. Because Syngene is itself a listed subsidiary, it should not be over-relied on as an asset that directly protects Biocon parent-company liquidity. Items to monitor include Syngene’s revenue growth, EBITDA margin, order book, client concentration, capex, dividends and cash balance.

The sixth downside scenario is deterioration in the US policy, pricing and litigation environment. Drug-pricing restraint, reimbursement changes, worse PBM/contracting terms, originator litigation and settlement terms, and early entry by competing products in the US would reduce the profitability of biosimilars and complex generics. Because Biocon has high US dependence, one regulatory change or product-group price decline in the US could alter expectations for consolidated EBITDA.

In practical monitoring terms, FY27 quarterly results should first be used to track Biosimilars revenue, EBITDA margin, Generics margin, Syngene growth, finance charges, gross debt, cash and current borrowings. Next, investors should track inspection/approval status from the FDA, EMA, Health Canada, PMDA and other regulators; new product launch performance; and sales progress for Denosumab, Aflibercept, Ustekinumab, insulin and GLP-1-related products. Finally, investors should monitor SGX disclosures related to the BBL secured notes, rating actions, completion of the QIP/BBL integration, and the debt maturity profile. If several of these items move in a weaker direction at the same time, the current improvement trend would be prone to stall.

11. Credit View and Monitoring Focus

Biocon’s current credit strength is positioned as high bank credit quality on a domestic parent-company basis, but as an improving high-yield credit from the standpoint of international foreign-currency investors in BBL/BBGP notes. As of FY26, the direction of credit strength is modestly improving, but that improvement assumes that operating margins, deleveraging, business integration and manufacturing-quality remediation proceed as planned. FY26 improvement is visible in EBITDA, debt balances and equity figures, but confirmation from operating cash flow and FCF awaits the FY26 annual report. The probability that the level or direction of credit strength changes rapidly is moderate; a single quarterly result alone is unlikely to change the view significantly, but FDA developments, US pricing, BBGP notes terms or a large capital-structure event could change the view relatively quickly.

Credit strength is supported, first, by the Biosimilars business platform and FY26 margin improvement. BBL has commercialised products, a sales platform across more than 120 countries, developed-market exposure and emerging-market tenders, and in FY26 it functioned as the centre of consolidated EBITDA. Second is capital-structure improvement through the QIP and structured debt repayment. FY26-end gross borrowings declined, equity became thicker, and S&P and Fitch rating actions reflected deleveraging expectations. Third is revenue diversification from Generics and Syngene. Compared with a single-product biotech company, Biocon has multiple revenue sources.

At the same time, many factors continue to constrain credit strength. The most important are dependence on the US market, biosimilar price competition, and manufacturing quality/FDA inspections. Because the success of Biosimilars supports consolidated credit strength, approval delays, price declines or supply problems in that segment would have a large impact. In addition, EBITDA improved in FY26, but finance charges, depreciation and amortisation, R&D and capex remain heavy, and the depth of reported net profit and FCF has not yet been sufficiently confirmed. Operating cash flow and FCF need to be rechecked in the FY26 annual report.

From a bondholder standpoint, investors need to go one level deeper than Biocon’s consolidated improvement and confirm the location of debt as well as guarantees and collateral. Biocon Limited’s CRISIL AA+ is a domestic-scale rating on domestic bank facilities and does not imply legal protection for the BBGP notes. The BBGP notes are secured notes of the BBL group, and S&P and Fitch ratings indicate an improving direction, but any Biocon Limited parent guarantee, collateral scope, restricted group and covenants need to be confirmed in the offering circular. Syngene’s earnings and cash are also subject to listed-subsidiary and minority-interest constraints, so consolidated leverage should be adjusted when assessed.

In terms of investment stance, Biocon/BBL is a credit to hold or consider while confirming business improvement and deleveraging; it is not a stable high-grade credit that can be left unattended. Because spread and price data have not been confirmed, this report does not conclude whether the bonds are cheap or rich. On credit fundamentals alone, if Biosimilars margins are maintained in FY27, gross debt declines further, FDA/quality issues do not worsen, and uncertainty around business integration and the BBGP notes terms declines, the credit view on the BBL notes should improve. Conversely, if the company stumbles on US pricing or manufacturing quality and net debt / EBITDA returns to the mid-3x range, rating-upgrade expectations would be easy to lose.

Monitoring should track FY27 quarterly Biosimilars revenue and EBITDA, Generics margin, Syngene growth, net debt, cash and bank balances, current borrowings, finance charges and capex. In addition, investors should monitor FDA/EMA/PMDA/Health Canada inspections and approvals, S&P/Fitch/CRISIL rating actions, BBGP notes SGX disclosures, completion status of the BBL ownership and capital-structure simplification, and the cash flow and debt maturity schedule in the FY26 annual report. In particular, whether the FY26 improvement is converting into operating cash flow and FCF, and how much freely available parent-company/BBL cash exists excluding Syngene, will be central to the next update.

12. Short Summary & Conclusion

Biocon is an India-origin global biopharmaceutical group and a composite credit combining BBL’s biosimilars business, Generics and Syngene’s CRDMO business. In FY26, credit strength moved in an improving direction due to Biosimilars growth, margin improvement, the QIP and debt reduction. However, this view remains provisional pending confirmation of operating cash flow and FCF, and the BBL/BBGP notes remain a high-yield-like credit for which investors should continue to monitor US regulatory and pricing risk, manufacturing quality and the subsidiary debt structure.

13. Sources

Confirmed Sources

• Biocon Limited, "Biocon Q4FY26 Total Income at Rs 4,569 Cr..." press release, 2026-05-07. https://www.biocon.com/biocon-q4fy26-revenue/
• Biocon Limited, Q4FY26 Fact Sheet, March 2026. https://www.biocon.com/docs/FactSheet-Q4FY26.pdf
• Biocon Limited, Integrated Annual Report FY2025. https://www.biocon.com/docs/Biocon_Integrated_Annual_Report_2025.pdf
• Biocon Limited, "Biocon Limited to Integrate Biocon Biologics Limited to Create a Unified Global Biopharmaceutical Leader", 2025-12-06. https://www.biocon.com/biocon-limited-to-integrate-biocon-biologics-limited-to-create-a-unified-global-biopharmaceutical-leader/
• CRISIL Ratings, "Biocon Limited Ratings reaffirmed at CRISIL AA+ / Stable / CRISIL A1+", 2025-12-16. https://www.crisil.com/mnt/winshare/Ratings/RatingList/RatingDocs/BioconLimited_December%2016_%202025_RR_385018.html
• Biocon Biologics, "S&P Global Upgrades Biocon Biologics Credit Rating To 'BB+' Revises Outlook to Stable", 2026-01-28. https://www.bioconbiologics.com/sp-global-upgrades-biocon-biologics-credit-rating-to-bb-revises-outlook-to-stable/
• Biocon Limited, "Fitch Ratings Revises Biocon Biologics Outlook from Stable to Positive", 2026-02-07. https://www.biocon.com/fitch-ratings-revises-biocon-biologics-outlook-from-stable-to-positive/
• Biocon Biologics, "Biocon Biologics Refinances USD 1.1 Billion Long Term Debt through USD Bonds and New Syndicated Facility", 2024-10-03. https://www.biocon.com/docs/Biocon_Biologics_Refinancing_PR_Oct3.pdf
• Biocon Limited, company statements page for FDA/VAI and regulatory updates, checked 2026-05-13. https://www.biocon.com/news-biocon/company-statements/

Unverified / Pending

• The FY2026 audited annual report and full cash flow statement had not yet been used in this draft. FY26 operating cash flow, FCF, debt maturity schedule and covenant headroom are items for the next review.
• The offering circular, indenture, guarantor list, collateral package, restricted group, change of control provisions, restricted payments and early redemption terms of the Biocon Biologics Global Plc USD notes are unverified.
• The final legal completion status of BBL becoming a wholly owned subsidiary, remaining consideration, and impact on the terms of each debt instrument need to be rechecked in stock exchange filings and the FY26 annual report.
• Bond prices, yields, OAS, Z-spreads and peer spreads from Bloomberg and other sources are unverified, and this report does not make a relative-value conclusion.
• Product-level pricing in the US and Europe, PBM/payor contracts, litigation settlement terms, product-level margins and detailed Syngene customer concentration are unverified.